Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer

SIMPLE SUMMARY: Targeted radionuclide therapy (TRT) delivers cancer-selective radiopharmaceuticals to eradicate cancer cells while sparing healthy tissue. The recent development of combinatory treatments is a growing research field in nuclear medicine to enhance cancer cytotoxicity of TRT. Among pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Grzmil, Michal, Wiesmann, Fabius, Schibli, Roger, Behe, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817840/
https://www.ncbi.nlm.nih.gov/pubmed/36612012
http://dx.doi.org/10.3390/cancers15010017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817840/
https://www.ncbi.nlm.nih.gov/pubmed/36612012
http://dx.doi.org/10.3390/cancers15010017

Ejemplares similares